Abbott Laboratories $ABT Shares Sold by Summit Global Investments

Summit Global Investments lowered its stake in Abbott Laboratories (NYSE:ABT) by 86.2% in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 9,943 shares of the healthcare product maker’s stock after selling 62,345 shares during the quarter. Summit Global Investments’ holdings in Abbott Laboratories were worth $1,332,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. IMG Wealth Management Inc. increased its stake in Abbott Laboratories by 759.1% during the 2nd quarter. IMG Wealth Management Inc. now owns 189 shares of the healthcare product maker’s stock worth $26,000 after buying an additional 167 shares during the period. Cloud Capital Management LLC acquired a new stake in shares of Abbott Laboratories during the third quarter valued at about $29,000. Anfield Capital Management LLC increased its position in shares of Abbott Laboratories by 81.3% during the second quarter. Anfield Capital Management LLC now owns 232 shares of the healthcare product maker’s stock worth $32,000 after acquiring an additional 104 shares during the last quarter. Delos Wealth Advisors LLC purchased a new position in Abbott Laboratories in the second quarter valued at about $32,000. Finally, Copia Wealth Management acquired a new stake in Abbott Laboratories during the 3rd quarter valued at approximately $38,000. Hedge funds and other institutional investors own 75.18% of the company’s stock.

Abbott Laboratories Trading Up 3.0%

Shares of NYSE:ABT opened at $109.31 on Friday. The company has a quick ratio of 1.24, a current ratio of 1.70 and a debt-to-equity ratio of 0.23. The company’s 50-day moving average price is $122.77 and its 200 day moving average price is $127.49. The company has a market cap of $190.08 billion, a PE ratio of 29.39, a P/E/G ratio of 1.69 and a beta of 0.72. Abbott Laboratories has a fifty-two week low of $105.27 and a fifty-two week high of $141.23.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 EPS for the quarter, meeting the consensus estimate of $1.50. The company had revenue of $11.46 billion for the quarter, compared to analyst estimates of $11.80 billion. Abbott Laboratories had a net margin of 14.72% and a return on equity of 17.94%. Abbott Laboratories’s revenue was up 4.4% compared to the same quarter last year. During the same quarter last year, the business earned $1.34 earnings per share. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. Sell-side analysts anticipate that Abbott Laboratories will post 5.14 earnings per share for the current year.

Abbott Laboratories Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, February 13th. Shareholders of record on Thursday, January 15th will be given a dividend of $0.63 per share. This is a boost from Abbott Laboratories’s previous quarterly dividend of $0.59. The ex-dividend date is Thursday, January 15th. This represents a $2.52 dividend on an annualized basis and a yield of 2.3%. Abbott Laboratories’s payout ratio is presently 67.74%.

Analyst Ratings Changes

Several equities analysts have recently commented on ABT shares. Barclays increased their target price on Abbott Laboratories from $162.00 to $169.00 and gave the company an “overweight” rating in a research note on Monday, January 5th. Piper Sandler reduced their price objective on shares of Abbott Laboratories from $150.00 to $135.00 and set an “overweight” rating on the stock in a research note on Friday, January 23rd. Jefferies Financial Group boosted their target price on shares of Abbott Laboratories from $145.00 to $149.00 and gave the stock a “buy” rating in a research report on Thursday, October 16th. Daiwa Capital Markets upped their target price on shares of Abbott Laboratories from $134.00 to $136.00 and gave the company an “outperform” rating in a research note on Tuesday, October 21st. Finally, Argus decreased their price target on Abbott Laboratories from $150.00 to $140.00 in a research note on Tuesday. One analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and four have given a Hold rating to the stock. According to MarketBeat, Abbott Laboratories currently has a consensus rating of “Moderate Buy” and a consensus target price of $140.75.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.